Northwestern University Human Resources

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Established: 1851-01-28

Employees: 5K

Market Cap: -

Website: https://www.venturecat.northwestern.edu

Clinical Trials

Memory and Fear Study (Fear of Memory Loss Study)

Not Applicable

Completed

Conditions: Anxiety and Fear

Interventions: Behavioral: Tailored Mindfulness Program for Fear of Memory Loss
Behavioral: Conventional Mindfulness Program

First Posted Date: 2021-03-30

Last Posted Date: 2024-05-16

Lead Sponsor: Northwestern University

Target Recruit Count: 81

Registration Number: NCT04821960

Locations: 🇺🇸
Northwestern University, Chicago, Illinois, United States

Promoting Infant-Directed Speech in Ghana

Not Applicable

Completed

Conditions: Infant Development

Interventions: Behavioral: Infant Directed Speech (IDS) Video + IDS Wall Calendar

First Posted Date: 2021-03-19

Last Posted Date: 2024-07-24

Lead Sponsor: Northwestern University

Target Recruit Count: 2800

Registration Number: NCT04807907

Locations: 🇺🇸
Northwestern University, Evanston, Illinois, United States

Accupressure of P6 to Reduce Nausea During Cesarean Section

Not Applicable

Completed

Conditions: Pregnancy Related
Cesarean Delivery
Vomiting
Nausea

Interventions: Other: Magnet at P6
Other: Magnet applied to arm not at P6 pressure point.

First Posted Date: 2021-03-16

Last Posted Date: 2024-02-29

Lead Sponsor: Northwestern University

Target Recruit Count: 200

Registration Number: NCT04799587

Locations: 🇺🇸
Northwestern Memorial Hospital, Chicago, Illinois, United States

Short Vs Standard Length Myotomy in Achalasia

Not Applicable

Completed

Conditions: Achalasia

Interventions: Procedure: Standard Length Myotomy
Procedure: Short Myotomy

First Posted Date: 2021-03-15

Last Posted Date: 2024-03-15

Lead Sponsor: Northwestern University

Target Recruit Count: 60

Registration Number: NCT04798547

Locations: 🇺🇸
Northwestern Memorial Hospital, Chicago, Illinois, United States

Brentuximab Vedotin and Pembrolizumab in Treating Patients With Recurrent Peripheral T-Cell Lymphoma

Phase 2

Withdrawn

Conditions: Recurrent Follicular T-Cell Lymphoma
Refractory Enteropathy-Associated T-Cell Lymphoma
Refractory Hepatosplenic T-Cell Lymphoma
Recurrent Angioimmunoblastic T-Cell Lymphoma
Refractory Follicular T-Cell Lymphoma
Refractory Nodal Peripheral T-Cell Lymphoma With TFH Phenotype
Refractory Subcutaneous Panniculitis-Like T-Cell Lymphoma
Recurrent Nodal Peripheral T-Cell Lymphoma With TFH Phenotype
Refractory Angioimmunoblastic T-Cell Lymphoma
Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified

Interventions: Drug: Brentuximab Vedotin
Biological: Pembrolizumab

First Posted Date: 2021-03-12

Last Posted Date: 2023-10-10

Lead Sponsor: Northwestern University

Registration Number: NCT04795869

Locations: 🇺🇸
Northwestern University, Chicago, Illinois, United States

The COCOA-PAD II Trial

Phase 3

Recruiting

Conditions: Peripheral Artery Disease

Interventions: Drug: cocoa flavanols
Drug: placebo

First Posted Date: 2021-03-12

Last Posted Date: 2025-05-15

Lead Sponsor: Northwestern University

Target Recruit Count: 190

Registration Number: NCT04794530

Locations: 🇺🇸
University of Chicago, Chicago, Illinois, United States
🇺🇸
Northwestern University, Chicago, Illinois, United States
🇺🇸
University of Minnesota, Minneapolis, Minnesota, United States